Lisa Williams, Carina Werkander Harstäde, Natalie Anderson, Ashwini Deshmukh, Alison Gayton, Merryn Gott, Ping Guo, Jane Nicol, Tatiana Tavares, Susan Waterworth
Nursing students' reactions to a graphic novel: A multi-national descriptive qualitative study
Nurse education today
patented medicine prices review board pmprb agency regulates prices patented medicines canada published proposed amendments regulatory framework december 2017 series changes delays revised policy yet finalized sought evaluate potential early impact uncertainty pmprb policy patentedmedicine launches developed retrospective cohort patented medicines molecules sold canada 13 countries pmprb currently uses proposed use price comparators sales data iqvia midas database 20122021 outcome whether molecule launched ie sold specific country within 2 years global first launch 2yr launch compared change 2year launch 20122017 proposed amendments published uncertain period 20182021 canada change united states 12 countries group othercountries group using interrupted time series logistic regressions respectively conducted analyses individual country subgroups molecule characteristics therapeutic benefit separately included 242 107 new molecules launched publication proposed amendments uncertain period respectively corresponding 2year launch proportions 450 308 canada 814 822 us 839 701 othercountries group analyses showed changes 2year launch uncertain period us othercountries group similar changes canada greater decreases observed norway sweden canada 2year launch proportion molecules major therapeutic benefit decreased 458 313 canada uncertain period 875 625 othercountries group increased 917 100 us negative impact pmprbpolicy uncertainty molecule launches observed comparing canada pricecomparator countries except molecules major therapeutic benefit reduction launches medicines major therapeutic benefit canada requires continuing investigation